QUOTED. 10 January 2020. Francis deSouza.
Illumina Inc. has agreed to pay $98m to terminate its merger agreement with Pacific Biosciences of California Inc. following opposition from antitrust regulators in the US and UK. See what Illumina CEO Francis deSouza said about it here.
“We believe this proposed combination would have broadened access to Pacific Biosciences' sequencing technology, significantly expanded and accelerated innovation, and ultimately increased the clinical utility and impact of sequencing.” – Francis deSouza, CEO, Illumina Inc.
Click here for a free trial of Medtech Insight